[go: up one dir, main page]

WO2010119300A2 - Suspension d'acétate de dexaméthasone à usage oral – composition masquant le goût de la dexaméthasone - Google Patents

Suspension d'acétate de dexaméthasone à usage oral – composition masquant le goût de la dexaméthasone Download PDF

Info

Publication number
WO2010119300A2
WO2010119300A2 PCT/GR2010/000018 GR2010000018W WO2010119300A2 WO 2010119300 A2 WO2010119300 A2 WO 2010119300A2 GR 2010000018 W GR2010000018 W GR 2010000018W WO 2010119300 A2 WO2010119300 A2 WO 2010119300A2
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
dexamethasone
dexamethasone acetate
acetate
vehicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GR2010/000018
Other languages
English (en)
Other versions
WO2010119300A3 (fr
WO2010119300A9 (fr
Inventor
Angelos Kassotakis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CASSO PHARMACEUTICALS Ltd
Original Assignee
CASSO PHARMACEUTICALS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CASSO PHARMACEUTICALS Ltd filed Critical CASSO PHARMACEUTICALS Ltd
Priority to EP10719774A priority Critical patent/EP2477604A2/fr
Publication of WO2010119300A2 publication Critical patent/WO2010119300A2/fr
Publication of WO2010119300A3 publication Critical patent/WO2010119300A3/fr
Publication of WO2010119300A9 publication Critical patent/WO2010119300A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Definitions

  • the invention related to a immediate release pharmaceutical formulation for oral administration comprising an effective amount of dexamethasone acetate in an aqueous ,pharmaceutically acceptable vehicle and a suspending agent
  • Dexamethasone a corticosteroid ,used in inflammatory and autoimmune disorders, usually formulated into tablets and liquid formulations for oral delivery.
  • Commercially available oral liquid formulations of dexamethasone comprising soluble salts of dexamethasone esters, for example dexamethasone sodium phosphate.
  • dexamethasone sodium phosphate.
  • the bad taste of these solutions .extensively described in the literature ,results in poor patient compliance .
  • the bad taste of dexamethasone and its soluble esters are dose dependent it is a considerable problem for the patient to comply especially in case of therapies require high doses of dexamethasone.
  • the problem is to create a palatable, stable, immediate release oral liquid dosage form of dexamethasone especially when high therapeutic doses of dexamethasone are needed
  • Dexamethasone acetate (the insoluble acetate ester of dexamethasone) has been previously used in formulations for local administration -including ophthalmic formulations-,as well as in parenteral ( intramuscular) formulations , but it has not been previously used in oral liquid formulations for immediate release dosage forms
  • dexamethasone acetate can be used for the preparation of a suspension of dexamethasone ,in which dexamethasone acetate has the attribute to mask the bad and exceptionally bitter taste of dexamethasone .
  • This attribute becomes perceptible particular when high doses of the said active ingredient are needed to be administered.
  • specific excipients that are known to the skilled person it can be prepared a immediate release ,stable formulation ,with components mutually compatible and stable during the shelf life of the product as it is determined from the rules governing the medicinal products for human use.
  • Dexamethasone acetate possess specific advantages compared to other dexamethasone esters for this specific purpose a) Immediate release of the active ingredient dexamethasone in the low pH of the gastric fluids (1-2), according to the literature b) Low solubility. Dexamethasone acetate does not dissolved in the aqueous conditions of the mouth cavity, and the interactions between the bitter molecule of dexamethasone and the taste buds of the tongue are prevented.
  • the formulation of the present invention is a palatable, oral aqueous suspension of dexamethasone in which dexamethasone is in the form of the its acetate ester and in concentration between about 0.4 mg/ml to about 40 mg/ml , more preferably between 0.4 mg/ml to about 10mg/ml,more preferably 4 mg/ml
  • the present invention is an aqueous suspension in which dexamethasone is dispersed in a medium-vehicle, that comprised mainly from water and may include propylene glycol and glycerin .
  • Dexamethasone acetate is evenly dispersed in the liquid aqueous vehicle.
  • the suspension has homogeneity so the active ingredient is uniformly dispersed, but undissolved in the vehicle-aqueous medium.
  • the medium can also comprise other pharmaceutical excipients that are mutually compatible at room temperature and they can form a pharmaceutically acceptable oral liquid preparation.
  • the aqueous vehicle serves as the external phase for the suspensions.
  • the vehicle may comprised of water ,glycerin , propylene glycol and mixtures there of.
  • the water comprising from about 30 to about 70% of the vehicle.
  • Glycerin may comprise up to 50 % of the vehicle.
  • the vehicle may also contain propylene glycol up to 20% of the vehicle.
  • Purified water that is the main ingredient of the vehicle component, comprising from about 30 to about 70% (w/w) of the formulation.
  • Water concentration is about 30% to 40% (w/w) in the final formulation
  • the particle size is very important for the bio availability of the product .
  • the active surface area is increased and the dissolution time is also increased .
  • the increased surface area may result in some agglomeration affecting the stability of the suspension or increase the oxidation and hydrolysis of the active compound resulting in faster degradation of dexamethasone.
  • Dexamethasone acetate of the inventive formulation has a median particle size of l ⁇ m to about 30 ⁇ m, more preferably about 3 ⁇ m to about 15 ⁇ m .
  • the particle size can be achieved using established methods well known to the skilled person like air jet milling, ball milling, mortal milling or any other approved method to decrease the particle size.
  • dexamethasone acetate particles of the disclose formulation were micronised using Jet Mil 50 (Jet Pharma S.A.)
  • the viscosity may be about 80 to about 2000 cps ,more preferably about 100 to about 500 cps,most preferably about 100 to 150cps.
  • the active ingredient particles maybe crystals that neither dissolve or grow substantially when the sample is heated to 45 0 C and cooled to room temperature repeatedly
  • the size of the particles may be measured using light scattering device ,sedimentation methods, or any other methods known to the skilled person .
  • Pharmaceutical excipients are pharmaceutically approved components of virtually all the pharmaceutical formulations. Excipients serve many different and wide purposes during the process of formulation as well as in the final formulation it self.
  • the inventive pharmaceutical suspension may comprise at least one of the additional component excipient selected form the following groups of excipients: surface active agents ,dispersing agents , sweetening agents, flavoring agents, coloring agents, buffers, salts, preservatives, oily vehicles, wetting agents, demulcents, spreading agents, stabilizers, antioxidants, antibiotic ,antifungal agents .
  • Poloxamer 188 found to be effective , in concentrations at about 0.05 to 0.5% without create excessive foaming and without alter the taste of the inventive composition .
  • Spreading agents like maltitol, mannitol, polyethylene glycol, and sorbitol can be added to the vehicle components in order to adjust the spreadability of the final suspension.
  • the present embodiment of the invention and due to the low concentration of Xantham Gum and the low viscosity of the suspension there is no need to adjust spreadability .Notwithstanding the use of such spreading agents cannot be excluded in other embodiments of the present invention where the higher viscosity could be higher.
  • sorbitol and mannitol also serve as an immediate on set sweetener and for this purpose used also in the present invention. In the present embodiment it has been used sorbitol solution 70% (w/w) in concentration less than 20% (w/w) ,even more less than 15%(w/w),to about 10 to 15% (w/w) of the final formulation
  • the suspension of the present invention may contain EDTA.
  • EDTA is a chelating agent that creates stable complexes with metals ions (alkaline earth , mainly Ca 2+ and Zn 2+ ) . The involvement of these metals in traces in catalyzing the auto oxidation, is an obvious possibility and has been reported in the literature.
  • EDTA is useful as an antioxidant, sequestering metal ions that otherwise catalyze autoxidation reactions. E.D.T.A. can also be serve as a preservative.
  • the stability of the suspension can be increased by the incorporation in the suspension a small amount of nitrogen- containing compound , such as niacinamide, creatinine and derivatives there of , like n-methylcreatinine .
  • nitrogen- containing compound such as niacinamide, creatinine and derivatives there of , like n-methylcreatinine .
  • antioxidants include , both inorganic and organic compounds .
  • Organic antioxidants such as Sodium Citrate penicillamine , pyridinesulfinic acid , thiourea and sodium formaldehyde sulfoxylate are acceptable .
  • Inorganic antioxidants such as sodium sulfite ,sodium metabisulf ⁇ te, sodium hypophosphite are acceptable.
  • inventive suspension contains sodium metabisulfite Suspending agents is another group of excipients.
  • the inventive formulation may contain xantham gum in a concentration from about 0.1% (w/w) at about 0.3% ,more preferably between 0.1 to 0.25 ,most preferably 0.17% (w/w).
  • a bacteriogical preservative for example , like sodium benzoate , methyl-paraben, propyl paraben, butyl-paraben , other antimicrobial agents can also be used in concentration and limits described in the pharmaceutical literature .
  • the inventive formulation may comprise sweeteners for making the inventive formulation even more palatable.
  • the present invention comprise at least one sweetener immediate onset and at least one sweetener delayed on set .
  • the present invention comprise aspartame and neohesperidin.
  • the present embodiment of the invention comprised of sorbitol solution (70%) in a concentration less than 20% (w/w) more preferably less than 15% (w/w),at about 10 to 15% of the final formulation.
  • organoleptic agents include coloring and flavoring agents and masking agents and can be incorporated to the inventive formulation for making it even more palatable.
  • the shelf life of the product may be six ,twelve, eighteen ,twenty four months, thirty or thirty six months as it can be determined by according to the regulatory stability testing of the final formulation and described by the rules governing the medicinal products for human use.
  • the dexamethasone acetate suspension contain the following ingredients TABLE 1
  • Mint Flavor (Tagasago Peppermint flavor 10324199) 0.11

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention concerne une composition pharmaceutiquement acceptable sous la forme d'une suspension d'acétate de dexaméthasone destinée à être administrée par voie orale. Dans ladite composition, le principe actif est dispersé de manière homogène dans un excipient-véhicule pharmaceutiquement acceptable. Cette invention concerne un procédé destiné à masquer le mauvais goût de la dexaméthasone, et une composition pharmaceutique comprenant un ester spécifique de dexaméthasone (acétate de dexaméthasone), en une quantité thérapeutiquement efficace dans un véhicule aqueux stable et compatible, et un agent de mise en suspension. La formulation selon l'invention comprend un acétate de dexaméthasone dispersé dans un véhicule aqueux compatible, à raison d'environ 0,4 à environ 40 mg/ml, de préférence, de 0,4 et environ 10 mg/ml, de préférence encore, de 4 mg/ml. Le véhicule aqueux peut, en outre, être constitué par du glycérol et du propylène glycol. La composition selon l'invention comprend plus d'un excipient pharmaceutique.
PCT/GR2010/000018 2009-04-14 2010-04-14 Suspension d'acétate de dexaméthasone à usage oral – composition masquant le goût de la dexaméthasone Ceased WO2010119300A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10719774A EP2477604A2 (fr) 2009-04-14 2010-04-14 Suspension d'acétate de dexaméthasone à usage oral composition masquant le goût de la dexaméthasone

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GR20090100230 2009-04-14
GR20090100230A GR20090100230A (el) 2009-04-14 2009-04-14 Απο του στοματος εναιωρημα οξικης δεξαμεθανοζης-συνθεση καλυψης γευσης της δεξαμεθανοζης

Publications (3)

Publication Number Publication Date
WO2010119300A2 true WO2010119300A2 (fr) 2010-10-21
WO2010119300A3 WO2010119300A3 (fr) 2011-03-24
WO2010119300A9 WO2010119300A9 (fr) 2011-07-28

Family

ID=42269791

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GR2010/000018 Ceased WO2010119300A2 (fr) 2009-04-14 2010-04-14 Suspension d'acétate de dexaméthasone à usage oral – composition masquant le goût de la dexaméthasone

Country Status (3)

Country Link
EP (1) EP2477604A2 (fr)
GR (1) GR20090100230A (fr)
WO (1) WO2010119300A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013149258A2 (fr) 2012-03-30 2013-10-03 Charles Drew University of Medicine and Science Compositions et procédés de traitement ou de prévention de troubles du syndrome métabolique
EP2658539A4 (fr) * 2010-12-27 2014-09-24 Samyang Biopharmaceuticals Composition de prévention des nausées et des vomissements
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US10561650B2 (en) 2013-03-14 2020-02-18 Christopher Brian Reid Method for treating a protozoal infection

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2159195A1 (en) 1971-11-10 1973-06-22 Fabre Sa Pierre Compsns contg sorbitol and a corticoid or pyrazolone - - suppression of ulcerogenic effects
US3962430A (en) 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
WO2005102287A2 (fr) 2004-04-22 2005-11-03 Duocort Ab Compositions pharmaceutiques pour therapie aux glucocorticoides aigue
US20060110331A1 (en) 2004-11-24 2006-05-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
WO2006061155A2 (fr) 2004-12-09 2006-06-15 Bayer Healthcare Ag Stabilisation d'esters de glucocorticoides au moyen d'acides
EP1795183A1 (fr) 2005-12-09 2007-06-13 Teva Pharmaceutical Industries, Inc. Dispersions ou solutions aqueuses de substances difficilement solubles et leurs procedés de préparation
US20090011045A1 (en) 2004-12-09 2009-01-08 Bayer Healthcare Ag Pharmaceutical for Hygienic Administration in the Ear
US9825993B2 (en) 2006-01-13 2017-11-21 Fortinet, Inc. Computerized system and method for advanced network content processing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066292A (en) * 1997-12-19 2000-05-23 Bayer Corporation Sterilization process for pharmaceutical suspensions
CN101190177B (zh) * 2006-11-24 2010-09-01 上海医药工业研究院 醋酸地塞米松局部成膜凝胶组合物及其应用

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2159195A1 (en) 1971-11-10 1973-06-22 Fabre Sa Pierre Compsns contg sorbitol and a corticoid or pyrazolone - - suppression of ulcerogenic effects
US3962430A (en) 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
WO2005102287A2 (fr) 2004-04-22 2005-11-03 Duocort Ab Compositions pharmaceutiques pour therapie aux glucocorticoides aigue
US20060110331A1 (en) 2004-11-24 2006-05-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
WO2006061155A2 (fr) 2004-12-09 2006-06-15 Bayer Healthcare Ag Stabilisation d'esters de glucocorticoides au moyen d'acides
US20090011045A1 (en) 2004-12-09 2009-01-08 Bayer Healthcare Ag Pharmaceutical for Hygienic Administration in the Ear
EP1795183A1 (fr) 2005-12-09 2007-06-13 Teva Pharmaceutical Industries, Inc. Dispersions ou solutions aqueuses de substances difficilement solubles et leurs procedés de préparation
US9825993B2 (en) 2006-01-13 2017-11-21 Fortinet, Inc. Computerized system and method for advanced network content processing

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Matersizer", 2000, MALVERN INSTRUMENTS LTD
B. FUSSNEGGER, BASF EXACT S, no. 3, November 1999 (1999-11-01), pages 9
OMEGA FARMA FARMACIA DE MUNIPULACAO, 6 September 2007 (2007-09-06)
SHANGHAI INST PHARM IND, 4 June 2008 (2008-06-04)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2658539A4 (fr) * 2010-12-27 2014-09-24 Samyang Biopharmaceuticals Composition de prévention des nausées et des vomissements
US9446052B2 (en) 2010-12-27 2016-09-20 Samyang Biopharmaceuticals Corporation Composition for prevention of nausea or vomiting
WO2013149258A2 (fr) 2012-03-30 2013-10-03 Charles Drew University of Medicine and Science Compositions et procédés de traitement ou de prévention de troubles du syndrome métabolique
US10561650B2 (en) 2013-03-14 2020-02-18 Christopher Brian Reid Method for treating a protozoal infection
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US11304961B2 (en) 2017-12-18 2022-04-19 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Also Published As

Publication number Publication date
GR20090100230A (el) 2010-11-18
WO2010119300A3 (fr) 2011-03-24
WO2010119300A9 (fr) 2011-07-28
EP2477604A2 (fr) 2012-07-25

Similar Documents

Publication Publication Date Title
US20100029714A1 (en) Aqueous pharmaceutical suspensions containing rebamipide and manufacturing process thereof
US20120238534A1 (en) Oral suspension of prednisolone acetate
KR100841893B1 (ko) 프레가발린 조성물
WO2012001093A2 (fr) Formulations liquides de fumarate de rupatadine
EP2741750A1 (fr) Composition pharmaceutique comprenant du céfuroxime
US20240374516A1 (en) Ready to use oral pharmaceutical suspension of dasatinib
EP2477604A2 (fr) Suspension d'acétate de dexaméthasone à usage oral composition masquant le goût de la dexaméthasone
ES2968899T3 (es) Formulación de la solución oral
KR20240105361A (ko) L-세린 또는 이의 약제학적으로 허용가능한 염의 액상 제제 및 이의 제조방법
DK2662093T3 (en) tobramycin
AU2017317523B2 (en) Pharmaceutical solution of Asenapine for sublingual or buccal use
JP5009707B2 (ja) 不快な味がマスキングされたキノロン系抗菌剤の経口投与用液剤
WO2006129160A2 (fr) Solutions aqueuses stables d'un agent antipsychotique
WO2012150607A2 (fr) Composition orale liquide comprenant du divalproex de sodium, et son procédé de préparation
JP4248795B2 (ja) 内服用液剤
KR102556874B1 (ko) 비스포스포네이트 및 콜레칼시페롤을 함유하는 경구용 에멀젼 조성물 및 그 제조방법
JP7768561B2 (ja) 液剤組成物
GR1009513B (el) Ποσιμα φαρμακευτικα διαλυματα που περιλαμβανουν καρβοκυστεϊνη
EP2656857A1 (fr) Formulation orale liquide
GR1009462B (el) Ποσιμο φαρμακευτικο διαλυμα με συγκαλυμμενη γευση
WO2017025930A1 (fr) Solution orale d'aripiprazole
CN115645357A (zh) 一种拉考沙胺口服溶液处方及其制备工艺
JP2025540537A (ja) フレカイニド含有液体医薬組成物及びその調製のためのプロセス
WO2018002738A1 (fr) Composition pharmaceutique liquide à goût masqué de (rs)-4-(éthyl [1- (4-méthoxyphényl) propan-2-yl] amino) butyl 3,4-diméthoxybenzoate ou de ses sels pharmaceutiquement acceptables
NZ614970B2 (en) A pharmaceutical composition for treating a disease in the oral cavity comprising rebamipide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10719774

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010719774

Country of ref document: EP